AP2006003786A0 - Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands - Google Patents
Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligandsInfo
- Publication number
- AP2006003786A0 AP2006003786A0 AP2006003786A AP2006003786A AP2006003786A0 AP 2006003786 A0 AP2006003786 A0 AP 2006003786A0 AP 2006003786 A AP2006003786 A AP 2006003786A AP 2006003786 A AP2006003786 A AP 2006003786A AP 2006003786 A0 AP2006003786 A0 AP 2006003786A0
- Authority
- AP
- ARIPO
- Prior art keywords
- histamine
- receptor ligands
- derivatives useful
- tetrahydronaphthyridine derivatives
- tetrahydronaphthyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04291222A EP1595881A1 (fr) | 2004-05-12 | 2004-05-12 | Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine |
| PCT/IB2005/001267 WO2005111036A1 (fr) | 2004-05-12 | 2005-05-06 | Derives de tetrahydronaphthyridine utilises comme ligands du recepteur h3 de l'histamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2006003786A0 true AP2006003786A0 (en) | 2006-10-31 |
Family
ID=34931096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2006003786A AP2006003786A0 (en) | 2004-05-12 | 2005-05-06 | Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7557121B2 (fr) |
| EP (2) | EP1595881A1 (fr) |
| JP (1) | JP4084410B2 (fr) |
| KR (1) | KR100908155B1 (fr) |
| CN (2) | CN1950371B (fr) |
| AP (1) | AP2006003786A0 (fr) |
| AR (1) | AR049092A1 (fr) |
| AT (1) | ATE491707T1 (fr) |
| AU (1) | AU2005243403B2 (fr) |
| BR (1) | BRPI0510762A (fr) |
| CA (1) | CA2564201C (fr) |
| CR (1) | CR8747A (fr) |
| DE (1) | DE602005025345D1 (fr) |
| DK (1) | DK1756104T3 (fr) |
| EA (1) | EA010487B1 (fr) |
| EC (1) | ECSP066984A (fr) |
| ES (1) | ES2355572T3 (fr) |
| GE (1) | GEP20084552B (fr) |
| GT (1) | GT200500112A (fr) |
| IL (1) | IL178882A (fr) |
| MA (1) | MA28579B1 (fr) |
| MX (1) | MXPA06013113A (fr) |
| NL (1) | NL1029016C2 (fr) |
| NO (1) | NO20064577L (fr) |
| PA (1) | PA8632801A1 (fr) |
| PE (1) | PE20060312A1 (fr) |
| SV (1) | SV2005002112A (fr) |
| TN (1) | TNSN06369A1 (fr) |
| TW (1) | TW200607506A (fr) |
| UY (1) | UY28895A1 (fr) |
| WO (1) | WO2005111036A1 (fr) |
| ZA (1) | ZA200609111B (fr) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6468306B1 (en) | 1998-05-29 | 2002-10-22 | Advanced Medical Optics, Inc | IOL for inhibiting cell growth and reducing glare |
| US7621949B2 (en) | 2003-12-09 | 2009-11-24 | Advanced Medical Optics, Inc. | Foldable intraocular lens and method of making |
| AU2006261162A1 (en) | 2005-06-17 | 2006-12-28 | Janssen Pharmaceutica N.V. | Naphthyridine compounds |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| CA2624625A1 (fr) * | 2005-11-04 | 2007-05-10 | Pfizer Limited | Derive de tetrahydronaphtyridine |
| WO2007099423A1 (fr) * | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3 |
| KR20080109841A (ko) | 2006-03-10 | 2008-12-17 | 뉴로젠 코포레이션 | 피페라지닐 옥소알킬 테트라히드로이소퀴놀린 및 관련유사체 |
| UA98772C2 (ru) | 2006-06-23 | 2012-06-25 | Эбботт Леборетриз | Производные циклопропиламина как модуляторы н3-гистаминового рецептора |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| US20100266504A1 (en) * | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
| WO2009082698A1 (fr) * | 2007-12-21 | 2009-07-02 | Abbott Laboratories | Compositions pour le traitement de troubles cognitifs |
| US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
| AU2009217361A1 (en) * | 2008-02-22 | 2009-08-27 | Irm Llc | Compounds and compositions as modulators of GPR119 activity |
| US20110046130A1 (en) * | 2008-03-31 | 2011-02-24 | Evotec Ag | Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
| WO2010026113A1 (fr) * | 2008-09-03 | 2010-03-11 | Evotec Neurosciences Gmbh | Acyl- et sufonyl-tétrahydronaphtyridines et dérivés aza de celles-ci en tant qu’antagonistes de récepteur d’histamine h3 |
| WO2010052222A1 (fr) * | 2008-11-07 | 2010-05-14 | Evotec Neurosciences Gmbh | Dérivés (dihydro)naphthyridinone comme antagonistes du récepteur h3 de l’histamine |
| US20120115900A1 (en) * | 2009-04-21 | 2012-05-10 | Neurosearch A/S | Substituted naphthyridine derivatives and their medical use |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| US8711772B2 (en) * | 2009-05-22 | 2014-04-29 | Qualcomm Incorporated | Paging of a user equipment (UE) within a wireless communications system |
| EP2451281A4 (fr) * | 2009-07-09 | 2013-03-13 | Merck Sharp & Dohme | Antagonistes des récepteurs à l'orexine à base de tétrahydronaphtyridine |
| WO2012037258A1 (fr) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Procédés de préparation de dérivés cyclopropyliques substitués en 1,2 |
| CN102093356B (zh) * | 2011-03-16 | 2012-12-19 | 无锡美克赛医药科技有限公司 | 一种2-氯-5,6,7,8-四氢-1,6-萘啶盐酸盐的制备方法 |
| EP2691393B1 (fr) | 2011-03-31 | 2016-09-14 | Pfizer Inc | Nouvelles pyridones bicycliques |
| WO2012172449A1 (fr) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactames convenant comme inhibiteurs des bêta-sécrétases |
| WO2013030713A1 (fr) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano[3,4-d][1,3]thiazine-2-amines |
| CA2872154C (fr) | 2012-05-04 | 2016-08-23 | Pfizer Inc. | Composes d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitues par des heterocycliques a titre d'inhibiteurs d'app, bace1 et bace2 |
| AP3902A (en) | 2012-06-29 | 2016-11-17 | Pfizer | Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors |
| WO2014045162A1 (fr) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2014091352A1 (fr) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1 |
| JP6162820B2 (ja) | 2012-12-19 | 2017-07-12 | ファイザー・インク | 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| WO2014125394A1 (fr) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Composés hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitués par un hétéroaryle |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| CA2900302C (fr) | 2013-02-19 | 2018-07-03 | Pfizer Inc. | Composes d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections |
| UA111696C2 (uk) | 2013-05-02 | 2016-05-25 | Пфайзер Інк. | Похідні імідазотриазину як інгібітори рde10 |
| EP3052495B1 (fr) | 2013-10-04 | 2019-06-26 | Pfizer Inc | Nouvelles pyridinones bicycliques utilisées comme modulateurs de gamma-sécrétase |
| EP3083618B1 (fr) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2 |
| BR112016022519A8 (pt) | 2014-04-01 | 2018-03-06 | Pfizer | cromeno e 1,1a,2,7b-tetra-hidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gama-secretase |
| EP3129388A1 (fr) | 2014-04-10 | 2017-02-15 | Pfizer Inc. | Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| JP6506833B2 (ja) | 2014-08-06 | 2019-04-24 | ファイザー・インク | イミダゾピリダジン化合物 |
| AU2016214102B2 (en) | 2015-02-03 | 2018-09-27 | Pfizer Inc. | Novel cyclopropabenzofuranyl pyridopyrazinediones |
| EP3303348B1 (fr) * | 2015-05-28 | 2019-08-07 | Theravance Biopharma R&D IP, LLC | Composés de naphthyridine en tant qu'inhibiteurs de kinases jak[ |
| SG10201912333PA (en) | 2015-06-17 | 2020-02-27 | Pfizer | Tricyclic compounds and their use as phosphodiesterase inhibitors |
| WO2017046675A1 (fr) | 2015-09-14 | 2017-03-23 | Pfizer Inc. | Nouveaux dérivés imidazo [4,5-c] quinoline et imidazo [4,5-c] [1,5] naphthyridine utilisés comme inhibiteurs de lrrk2 |
| JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド |
| EP3353174A1 (fr) | 2015-09-24 | 2018-08-01 | Pfizer Inc | N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides utiles comme inhibiteurs de bace |
| WO2017051303A1 (fr) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Dérivés de tétrahydropyrano[3,4-d] [1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace |
| BR112018015191B1 (pt) | 2016-02-23 | 2023-10-17 | Pfizer Inc | Compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida, seu uso e composição farmacêutica que os compreende |
| HUE054857T2 (hu) | 2016-07-01 | 2021-10-28 | Pfizer | 5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére |
| BR112019018688A2 (pt) | 2017-03-10 | 2020-04-07 | Pfizer | derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2 |
| EP3592740B1 (fr) | 2017-03-10 | 2022-02-09 | Pfizer Inc. | Dérivés cycliques substituées de l'imidazo[4,5c]quinoleine. |
| JP2020523035A (ja) | 2017-06-07 | 2020-08-06 | エーディーアールエックス， インコーポレイテッド | タウ凝集阻害剤 |
| HUE060914T2 (hu) | 2017-06-22 | 2023-04-28 | Pfizer | Dihidro-pirrolo-piridin származékok |
| EP3668886A2 (fr) | 2017-08-18 | 2020-06-24 | Adrx, Inc. | Inhibiteurs peptidiques d'agrégation de tau |
| ES2942837T3 (es) | 2018-03-23 | 2023-06-07 | Pfizer | Derivados de azaespiro piperazina |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| HUP9901190A3 (en) | 1996-02-09 | 2002-05-28 | Black James Foundation | Sulfonamide derivatives of imidazole, process for producing them and pharmaceutical compositions containing them |
| WO2000035296A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Liberation amelioree d'agents medicamenteux actifs par un enrobage de chewing-gum |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9803536D0 (en) | 1998-02-19 | 1998-04-15 | Black James Foundation | Histamine H,receptor ligands |
| EP0982300A3 (fr) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique |
| TWI298068B (en) * | 2000-06-21 | 2008-06-21 | Dainippon Sumitomo Pharma Co | Pharmaceutical composition for schizophrenia |
| AU2001273384A1 (en) | 2000-07-13 | 2002-01-30 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| AU8473301A (en) * | 2000-08-08 | 2002-02-18 | Ortho Mcneil Pharm Inc | Non-imidazole aryloxyalkylamines |
| JP2004511438A (ja) | 2000-08-08 | 2004-04-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | イミダゾールを含有しないアリールオキシピペリジン |
| AU2002254114A1 (en) | 2001-03-23 | 2002-10-08 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| GB0206033D0 (en) * | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| BRPI0413048A (pt) | 2003-07-29 | 2006-10-17 | Novo Nordisk As | composto, composição farmacêutica, uso de um composto, e, método para o tratamento de distúrbios ou doenças relacionados com o receptor h3 da histamina |
| CA2624625A1 (fr) * | 2005-11-04 | 2007-05-10 | Pfizer Limited | Derive de tetrahydronaphtyridine |
-
2004
- 2004-05-12 EP EP04291222A patent/EP1595881A1/fr not_active Withdrawn
-
2005
- 2005-05-06 KR KR1020067023573A patent/KR100908155B1/ko not_active IP Right Cessation
- 2005-05-06 AP AP2006003786A patent/AP2006003786A0/xx unknown
- 2005-05-06 BR BRPI0510762-8A patent/BRPI0510762A/pt not_active IP Right Cessation
- 2005-05-06 EA EA200601897A patent/EA010487B1/ru not_active IP Right Cessation
- 2005-05-06 CN CN2005800150008A patent/CN1950371B/zh not_active Expired - Fee Related
- 2005-05-06 AT AT05736116T patent/ATE491707T1/de not_active IP Right Cessation
- 2005-05-06 CA CA2564201A patent/CA2564201C/fr not_active Expired - Fee Related
- 2005-05-06 EP EP05736116A patent/EP1756104B1/fr active Active
- 2005-05-06 DE DE602005025345T patent/DE602005025345D1/de active Active
- 2005-05-06 DK DK05736116.4T patent/DK1756104T3/da active
- 2005-05-06 GE GEAP20059701A patent/GEP20084552B/en unknown
- 2005-05-06 AU AU2005243403A patent/AU2005243403B2/en not_active Ceased
- 2005-05-06 JP JP2007512575A patent/JP4084410B2/ja not_active Expired - Fee Related
- 2005-05-06 CN CN201010150783A patent/CN101798305A/zh active Pending
- 2005-05-06 ES ES05736116T patent/ES2355572T3/es active Active
- 2005-05-06 WO PCT/IB2005/001267 patent/WO2005111036A1/fr active Application Filing
- 2005-05-06 MX MXPA06013113A patent/MXPA06013113A/es active IP Right Grant
- 2005-05-11 AR ARP050101916A patent/AR049092A1/es unknown
- 2005-05-11 TW TW094115276A patent/TW200607506A/zh unknown
- 2005-05-11 NL NL1029016A patent/NL1029016C2/nl not_active IP Right Cessation
- 2005-05-12 PE PE2005000533A patent/PE20060312A1/es not_active Application Discontinuation
- 2005-05-12 SV SV2005002112A patent/SV2005002112A/es not_active Application Discontinuation
- 2005-05-12 PA PA20058632801A patent/PA8632801A1/es unknown
- 2005-05-12 US US11/128,804 patent/US7557121B2/en not_active Expired - Fee Related
- 2005-05-12 GT GT200500112A patent/GT200500112A/es unknown
- 2005-05-12 UY UY28895A patent/UY28895A1/es not_active Application Discontinuation
-
2006
- 2006-10-09 NO NO20064577A patent/NO20064577L/no not_active Application Discontinuation
- 2006-10-26 IL IL178882A patent/IL178882A/en not_active IP Right Cessation
- 2006-11-01 ZA ZA200609111A patent/ZA200609111B/xx unknown
- 2006-11-09 EC EC2006006984A patent/ECSP066984A/es unknown
- 2006-11-10 MA MA29447A patent/MA28579B1/fr unknown
- 2006-11-10 TN TNP2006000369A patent/TNSN06369A1/fr unknown
- 2006-11-10 CR CR8747A patent/CR8747A/es unknown
-
2009
- 2009-06-25 US US12/491,370 patent/US20090258861A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL178882A0 (en) | Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands | |
| IL180548A0 (en) | Piperidine derivatives as histamine h3 receptor ligands | |
| PL1802307T3 (pl) | Pochodne pirolidyny jako ligandy receptorów histaminowych | |
| TWI369356B (en) | Tetrahydropyridoindole derivatives | |
| ZA200703912B (en) | 3-arylamino pyridine derivatives | |
| AP2007003887A0 (en) | Pyridine derivatives | |
| IL180481A0 (en) | Aryl-pyridine derivatives | |
| HK1105971A1 (en) | Pyrrazolo-pyrimidine derivatives | |
| GB0512335D0 (en) | Merocyanine derivatives | |
| IL182585A0 (en) | Imidazo-benzodiazepine derivatives | |
| HK1100002A1 (en) | 4-phenyl-pyrimidine-2-carbonitrile derivatives | |
| EP1713917A4 (fr) | Derives de pneumolysine | |
| HK1092469A1 (en) | Benzothiazole derivatives as adenosine receptor ligands | |
| HK1100775A1 (en) | 4-Amino-5-cyanopyrimidine derivatives | |
| GB0414272D0 (en) | OsK1 derivatives | |
| IL188924A0 (en) | Imidazopyridine derivatives as cannabinoid receptor ligands | |
| ZA200705106B (en) | Nicotinic acetycholine receptor ligands | |
| IL182001A0 (en) | 2-acylaminothiazole derivatives | |
| ZA200800354B (en) | Imidazopyridine derivatives as cannabinoid receptor ligands | |
| GB0411078D0 (en) | Bicyclic derivatives | |
| GB0416524D0 (en) | Pyridine derivatives | |
| ZA200600676B (en) | Pyridazinyl-piperazines and their use as histamine H3 receptor ligands | |
| GB0422397D0 (en) | 3-Cyano-Quinoline derivatives | |
| GB0405905D0 (en) | Azaquinazoline derivatives |